Featured Story

  • Michigan investigators finger ATDC gene for aggressive pancreatic cancer

    Pancreatic cancer has long loomed as one of the most aggressive killers, typically leaving patients with a poor prognosis and specialists with few options for effective treatment. But now a team at the University of Michigan in Ann Arbor says they have new reason to believe that a particular gene is responsible for the fast-spreading cancer--offering a clear target for drug developers.

Genetic error highlights a new approach to Fragile X syndrome

Investigators say that a single mutation in the gene linked to Fragile X--which is the largest single-gene cause of autism--can be tied to specific symptoms of the disease, suggesting that a new approach to treating the disease could work where others have failed.

Microbiome research opens a new pathway for autoimmune disease

The prospect that new research into the complex world of gut bacteria will deliver a whole new class of therapies has inspired the launch of a lineup of upstart biotechs. And now investigators in Belgium say they may have found a potentially compelling pathway for microbiome drug developers working in the autoimmune field.

Microcapsules shuttle promising protein to treat osteoarthritis

Building on years of research into the anti-inflammatory and tissue-repairing properties of the protein molecule C-type natriuretic peptide, investigators in the U.K. say they have managed to overcome one of the hurdles that has prevented its use for treating osteoarthritis.

Tracking tech illuminates T cells for immuno-oncology research

Researchers at Tübingen University say they have developed a new tracking technology that will allow those working in the field of immuno-oncology to understand better how these new therapies are working.

Amgen teams with MD Anderson on new BiTE programs for MDS

Fast on the heels of the FDA's approval of Blincyto (blinatumomab), Amgen's new leukemia fighter that uses a bispecific T cell engager system to flag cancer cells for the immune system to destroy, the Big Biotech has partnered up with MD Anderson in Texas on a new program aimed at identifying targets for this technology in myelodysplastic syndrome.


From Our Sister Sites


Merck is financing a $1.85 million study being conducted at Texas Tech University to see if lower dosages of its lucrative but controversial cattle growth drug Zilmax could allow the company to reintroduce the product to U.S. and global markets and kick-start sales.


A survey of 2,000 pet owners conducted by Bayer HealthCare Animal Health and the Companion Animal Parasite Council has revealed that when veterinarians provide information to clients about parasites prevalent in their area, they can drive up clinic visits.